November 2024 | Press Release
City Labs Receives NIH Award to Develop Leadless Pacemaker Betavoltaic Power Source
Miami, FL, November 14, 2024—City Labs has been awarded a Commercialization Readiness Pilot (CRP) from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. This significant funding will support the advancement of City Labs’ innovative betavoltaic battery for leadless pacemakers, employing scalable fabrication techniques to prepare the technology for pre-clinical testing.
Since 2019, the NHLBI has strongly supported City Labs’ mission to create a nuclear-powered battery that could revolutionize cardiac pacing technology. The new funding accelerates progress toward a device with a 20-year lifespan, offering substantial improvements over current leadless pacemakers, which typically last around 12 years. The limited battery life of existing devices restricts their use to older patients who are less likely to outlive the battery, avoiding the challenges of difficult retrieval and replacement surgeries.
By developing a long-lasting nuclear-powered pacemaker, City Labs aims to expand leadless pacing options to younger patients with arrhythmias, who can benefit from safer, less complication-prone treatment. In collaboration with BIOTRONIK, City Labs is advancing this groundbreaking technology, which promises to reduce complications associated with traditional transvenous pacemakers and set a new standard for patient outcomes.
This CRP award marks an important milestone in City Labs’ ongoing efforts to transform pacemaker technology and improve quality of life for millions worldwide.
About City Labs:
City Labs, Inc. is a Florida-based corporation specializing in designing, developing, and manufacturing ultra-low power, long-life (20+ years) tritium-powered nuclear batteries. These batteries are primarily used to power microelectronics, sensors, and other devices employed in the aerospace, defense, and industrial sectors. City Labs has a regulatory-licensed R&D/manufacturing facility located in Miami, Florida. For more information, visit citylabs.net.
About BIOTRONIK:
BIOTRONIK is a global leader in cardiovascular biomedical research and technology, headquartered in Berlin, Germany. The company specializes in developing innovative medical devices for cardiac rhythm management, electrophysiology, and vascular intervention. Biotronik is committed to delivering safe and reliable solutions that improve and save patient lives. For more information, visit biotronik.com.
For media inquiries or further information, please contact:
Johann Hernandez
305-909-7593 x108
